OptimizeRx (OPRX) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue grew 30% year-over-year to $21.3 million, driven by legacy HCP business, Medicx Health acquisition, and DAAP sales, though DTC softness was noted.

• Gross margin improved to 63.1% from 60% year-over-year, reflecting higher-margin solutions and favorable channel mix.

• Net loss widened to $9.1 million ($0.50/share) from $2.9 million, primarily due to a $7.5 million goodwill impairment.

• Integration of acquired businesses and DAAP platform adoption yielded higher-than-expected operating efficiencies and cost savings.

• The company is shifting DTC to a self-service model, leveraging proprietary Micro-Neighborhood targeting and expanding enterprise-level engagements.

Financial highlights

• Q3 2024 revenue: $21.3 million, up 30% from $16.3 million in Q3 2023; nine months: $59.8 million, up 39% year-over-year.

• Gross profit: $13.4 million (63.1% margin) in Q3 2024; nine months: $37.4 million (62.5% margin).

• Net loss: $9.1 million ($0.50/share) in Q3 2024, impacted by $7.5 million goodwill impairment.

• Non-GAAP net income: $2.3 million ($0.12/share) vs. $1.6 million ($0.09/share) in Q3 2023.

• Adjusted EBITDA: $2.7 million, up from $0.9 million in Q3 2023.

Outlook and guidance

• 2024 annual revenue guidance: $88–$92 million; Adjusted EBITDA expected between $8–$10 million.

• High visibility into Q4 revenue with minimal "go-get" required to meet guidance.

• Four clients expected to generate over $10 million each in 2025, with one client surpassing $15 million in 2024.

• Sufficient liquidity anticipated for the next 12 months; additional financing may be sought for acquisitions or strategic initiatives.

• Continued focus on self-service DTC, DAAP adoption, and cross-segment integration to drive future growth.